References
1. Kuriachan, V.P., G.L. Sumner, and L.B. Mitchell, Sudden Cardiac
Death. Current Problems in Cardiology, 2015. 40 (4): p.
133-200.
2. de Bakker, J.M., et al., Slow conduction in the infarcted human
heart. ’Zigzag’ course of activation. Circulation, 1993.88 (3): p. 915-26.
3. Sharma, P., et al., Short-term outcomes associated with
inpatient ventricular tachycardia catheter ablation. Pacing Clin
Electrophysiol, 2020. 43 (5): p. 444-455.
4. Maskoun, W., et al., Outcome of catheter ablation for
ventricular tachycardia in patients with ischemic cardiomyopathy: A
systematic review and meta-analysis of randomized clinical trials. Int
J Cardiol, 2018. 267 : p. 107-113.
5. Gunda, S., et al., Risk score model for predicting
complications in patients undergoing ventricular tachycardia ablation:
insights from the National Inpatient Sample database. Europace, 2019.21 (3): p. 475-483.
6. Bloom JE, Dinh DT, Noaman S, et al. Adverse impact of chronic kidney
disease on clinical outcomes following percutaneous coronary
intervention. Catheter Cardiovasc Interv. 2020;1–9.https://doi.org/10.1002/ccd. 29436).
7. Palaniswamy, C., et al., Catheter ablation of postinfarction
ventricular tachycardia: ten-year trends in utilization, in-hospital
complications, and in-hospital mortality in the United States. Heart
Rhythm, 2014. 11 (11): p. 2056-63.
8. Campbell, T., et al., Updates in Ventricular Tachycardia
Ablation. Korean Circ J, 2021. 51 (1): p. 15-42.
9. Cronin, E.M., et al., 2019 HRS/EHRA/APHRS/LAHRS expert
consensus statement on catheter ablation of ventricular arrhythmias.Europace, 2019. 21 (8): p. 1143-1144.
10. Pothineni, N.V., et al., Complication rates of ventricular
tachycardia ablation: Comparison of safety outcomes derived from
administrative databases and clinical trials. Int J Cardiol, 2015.201 : p. 529-31.
11. Maini, R., et al., Persistent Underrepresentation of Kidney
Disease in Randomized, Controlled Trials of Cardiovascular Disease in
the Contemporary Era. J Am Soc Nephrol, 2018. 29 (12): p.
2782-2786.
12. Cheung, J.W., et al., Outcomes, Costs, and 30-Day Readmissions
After Catheter Ablation of Myocardial Infarct-Associated Ventricular
Tachycardia in the Real World: Nationwide Readmissions Database 2010 to
2015. Circ Arrhythm Electrophysiol, 2018. 11 (11): p. e006754.
13. Calkins, H., et al., Cost-effectiveness of catheter ablation
in patients with ventricular tachycardia. Circulation, 2000.101 (3): p. 280-8.
14. Stompor, T., Coronary artery calcification in chronic kidney
disease: An update. World J Cardiol, 2014. 6 (4): p. 115-29.
15. Liu, P., et al., Acquired long QT syndrome in chronic kidney
disease patients. Ren Fail, 2020. 42 (1): p. 54-65.
16. Bonato, F.O.B. and M.E.F. Canziani, Ventricular arrhythmia in
chronic kidney disease patients. J Bras Nefrol, 2017. 39 (2):
p. 186-195.
17. Karmin O, Siow YL. Metabolic imbalance of homocysteine and hydrogen
sulfide in kidney disease. Curr Med Chem. 2018;25(3):367–377..